Evidence map›Paper›PMID 34527569›Full record

ArticleGland surgery2021

Antitumor activity of everolimus in recurrent metastatic endometrial cancer with

Xuhong Zhang, Junping Shi, Junying Li, Xiaoliang Shi, Xiaoliang Liu, Yingli Zhang, Yanzhi Cui

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Xuhong ZhangGynecology Department, Tianjin Department Medical University General Hospital, Tianjin, China.
Junping ShiOrigiMed Co. Ltd, Shanghai, China.
Junying LiOrigiMed Co. Ltd, Shanghai, China.
Xiaoliang ShiOrigiMed Co. Ltd, Shanghai, China.
Xiaoliang LiuOrigiMed Co. Ltd, Shanghai, China.
Yingli ZhangDepartment of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Yanzhi CuiDepartment of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Unimed Medical Institute · CNFourth Hospital of Hebei Medical University · CNTianjin Medical University General Hospital · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) is one of the most common gynecological tumors. The first-line treatment for advanced EC is chemoradiotherapy. However, patients in poor health, such as those with intestinal obstruction, have limited tolerance for the side effects of chemoradiotherapy. Individualized precision treatment may bring new hope to these patients. Herein, we have reported on a 56-year-old female patient with metastatic EC combined with severe intestinal obstruction. Due to her inability to tolerate needle biopsy and standard treatment protocols, next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) testing was performed and

Indexed as

case reportcirculating tumor DNA (ctDNA)Endometrial cancer (EC)everolimusPTEN deletion

Identifiers

PMID34527569
PMCPMC8411095
OpenAlexW3196170005

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.